Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Toxins In Silicone Tubing Leads To FDA Warning About Hemodialysis Machines Made By Fresenius

Executive Summary

Toxins that have been shown to cause adverse events in animals – including endocrine dysfunction and male reproductive effects – are emitted by tubing that’s part of Fresenius’ 2008T, 2008K2 and 2008K model devices, the US agency says in a letter to health care providers.

You may also be interested in...



FDA Rebukes Fresenius For Dragging Its Feet Over Toxins Risk

The US FDA issued a stern warning to Fresenius Medical Care over its slow approach to corrective actions over potentially harmful toxins emitted from its hemodialysis machines and accessories.

News We’re Watching: Apple Watch Imports Blocked, Fresenius Recall, Groups Ask For Longer LDT Comment Period

This week, the International Trade Commission ruled in favor of Masimo and blocked the import of some Apple Watches; Fresenius faced a recall; City of Hope announced a pancreatic cancer grant; and organizations asked for a longer comment period on the US FDA’s proposed rule on lab-developed tests.

Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot

In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel